The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies
We describe the downregulation of HER2 in gastric carcinoma cells upon HDACi treatment. Concomitantly, cells with high basal or treatment-induced HER2 expression showed most profound sensitivities towards HDACi. These findings may thus provide the basis for HDACi treatment as a therapeutic option particularly valuable in HER2-amplified gastric cancer and particularly useful in combination therapies with HER2 inhibitors.
Authors
- Robert Jenke (ORCID: https://orcid.org/0000-0002-4027-1249)
- Hannes Borchardt
- Finn K. Hansen (ORCID: https://orcid.org/0000-0001-9765-5975)
- Thomas Büch
- René Thieme
- Ines Gockel (ORCID: https://orcid.org/0000-0001-7423-713X)
- Achim Aigner (ORCID: https://orcid.org/0000-0002-2778-6256)
- Tim Kahl
- Tamara Zenz
Institutions
- University of Bonn (DE)
- Comprehensive Cancer Center Mainfranken (DE)
- University Hospital Leipzig (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2024-12-10
- DOI
- https://doi.org/10.4143/crt.2024.546
- Citations
- 1
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Deutsche Forschungsgemeinschaft